BioSpace News Archive

Promore Pharma Deregisters Warrants

Promore Pharma announces that the company has had 137 160 warrants deregistered, corresponding to a dilution of 0.2% in programs 1-2 issued to Technomark Group USA LLC and Kentron Biotechnology Pvt Ltd.

January 31, 2022
·
2 min read
Business

Fennec Pharmaceuticals Announces Management Change - Jan 31, 2022

Fennec Pharmaceuticals Inc. announced that Shubh Goel, the Company’s chief commercial officer, has tendered her resignation and will depart Fennec in late February.

January 31, 2022
·
4 min read
Biotech Beach

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program’s (CERP™) 100th published peer-reviewed study on the company’s flagship ingredient Niagen® (patented nicotinamide riboside, or “NR”) and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach such a milestone.

January 31, 2022
·
6 min read
Genetown

Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that two abstracts – including an oral presentation on MPS-1 – have been accepted for presentation at the upcoming 18th Annual WORLDSymposium™.

January 31, 2022
·
3 min read
Pharm Country

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

Passage Bio, Inc. announced its participation at the 18th Annual WORLDSymposium, a research conference dedicated to lysosomal diseases, taking place virtually and in person in San Diego, Calif., February 7 – 11, 2022.

January 31, 2022
·
6 min read
Drug Development

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced positive topline clinical data from the placebo-controlled, double-blind portion of its Phase 3 MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) safety study of resmetirom.

January 31, 2022
·
17 min read
Pharm Country

Walmart and Quest Diagnostics Empower People to Take Control of Their Healthcare Through New Consumer-Initiated Laboratory Testing Solution Powered by QuestDirect™ Through Walmart.com

Quest Diagnostics announced that they will now offer consumer-initiated laboratory testing powered by QuestDirect™ in collaboration with Walmart.

January 31, 2022
·
4 min read
Biotech Bay

Nevro to Present at Citi’s 2022 Virtual Healthcare Conference

Nevro Corp. announced that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern Time.

January 31, 2022
·
2 min read
BioCapital

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022

REGENXBIO Inc. (Nasdaq: RGNX) today announced that five oral and seven poster presentations will be presented at the 18th Annual WORLDSymposium™, taking place in San Diego, CA from February 7 through 11, 2022.

January 31, 2022
·
4 min read
BioMidwest

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Recorlev® (levoketoconazole) is now available for prescription.

January 31, 2022
·
15 min read